Antithrombotic stewardship

Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy during and after hospitalisation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28603

Enrollment

2000

Registered

2014-11-03

Start date

2015-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Included will be patients on antithrombotics (unfractionated heparin (UFH), low-molecular weight heparin (LMWH), VKA or NOAC.

Interventions

The intervention consists of the S-team, consisting of a specialized thrombosis nurse as casemanager, haematologist, medical leader Thrombosis Service, hospital pharmacist/clinical pharmacologist, car

Eligibility

Inclusion criteria

Inclusion criteria: Included will be patients on antithrombotics (unfractionated heparin (UFH), low-molecular weight heparin (LMWH), VKA or NOAC.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Composite endpoint: proportion of patients with equal or greater than 1 bleeding or equal or greater than 1 arterial/venous thrombotic events during and after hospitalization.	—

Secondary

Measure	Time frame
Each of the components of the primary endpoint separately (bleeding, thrombosis), severity of bleeding complication, length of hospital stay, patient related outcomes (quality of life, belief in medicines questionnaire [8], adherence; patient satisfaction), healthcare costs (labour costs versus costs for bleeding/thrombotic events (including use of antidotes), and cost-effectiveness analysis.	—

Contacts

Public ContactP.M.L.A. Bemt, van den

Erasmus MC Hospital Pharmacy P.O. Box 2040

p.vandenbemt@erasmusmc.nl+31 10 7033202

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)